Cargando…
Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy
Background and Objective: This study evaluated the relationship between microsatellite status (MSI) and pan-immune-inflammation score (PIV) in tumor response to neoadjuvant chemotherapy (NAC) in patients with clinical stage III gastric cancer (cStage III GC). Materials and Methods: Microsatellite in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537642/ https://www.ncbi.nlm.nih.gov/pubmed/37763744 http://dx.doi.org/10.3390/medicina59091625 |
_version_ | 1785113148677685248 |
---|---|
author | Gulmez, Ahmet Coskun, Hatice Koseci, Tolga Ata, Serdar Bozkurt, Berna Cil, Timucin |
author_facet | Gulmez, Ahmet Coskun, Hatice Koseci, Tolga Ata, Serdar Bozkurt, Berna Cil, Timucin |
author_sort | Gulmez, Ahmet |
collection | PubMed |
description | Background and Objective: This study evaluated the relationship between microsatellite status (MSI) and pan-immune-inflammation score (PIV) in tumor response to neoadjuvant chemotherapy (NAC) in patients with clinical stage III gastric cancer (cStage III GC). Materials and Methods: Microsatellite instability (MSI) status was evaluated based on pathology preparations. Pan-immune-inflammation score (PIV) was obtained from pre-treatment blood tests. The relationship of both parameters with pathological complete response (pCR) was evaluated. Results: A total of 104 patients were included in this study. All the patients were stage III GC patients receiving perioperative treatment. There were 13 patients in total who achieved a pCR response. While CNS was detected in 11 of the patients who achieved a pCR, the MSI status of the other two patients was unknown. No pCR was observed in any patient with MSI-H. According to the cut-off value for PIV, 25 (24%) patients were in the PIV-low (≤53.9) group, while 79 (76%) were in the PIV-high (>53.9) group. Based on univariate analysis, a higher PIV was associated with worse outcomes for pathological response, disease recurrence, and survival (p < 0.05). Conclusions: In patients with clinically stage III GC, the presence of MSI-H may predict no benefit from perioperative treatment. Conversely, a pre-treatment PIV score using specific cut-off values may provide a positive prediction of pathological response and survival. |
format | Online Article Text |
id | pubmed-10537642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105376422023-09-29 Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy Gulmez, Ahmet Coskun, Hatice Koseci, Tolga Ata, Serdar Bozkurt, Berna Cil, Timucin Medicina (Kaunas) Article Background and Objective: This study evaluated the relationship between microsatellite status (MSI) and pan-immune-inflammation score (PIV) in tumor response to neoadjuvant chemotherapy (NAC) in patients with clinical stage III gastric cancer (cStage III GC). Materials and Methods: Microsatellite instability (MSI) status was evaluated based on pathology preparations. Pan-immune-inflammation score (PIV) was obtained from pre-treatment blood tests. The relationship of both parameters with pathological complete response (pCR) was evaluated. Results: A total of 104 patients were included in this study. All the patients were stage III GC patients receiving perioperative treatment. There were 13 patients in total who achieved a pCR response. While CNS was detected in 11 of the patients who achieved a pCR, the MSI status of the other two patients was unknown. No pCR was observed in any patient with MSI-H. According to the cut-off value for PIV, 25 (24%) patients were in the PIV-low (≤53.9) group, while 79 (76%) were in the PIV-high (>53.9) group. Based on univariate analysis, a higher PIV was associated with worse outcomes for pathological response, disease recurrence, and survival (p < 0.05). Conclusions: In patients with clinically stage III GC, the presence of MSI-H may predict no benefit from perioperative treatment. Conversely, a pre-treatment PIV score using specific cut-off values may provide a positive prediction of pathological response and survival. MDPI 2023-09-08 /pmc/articles/PMC10537642/ /pubmed/37763744 http://dx.doi.org/10.3390/medicina59091625 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gulmez, Ahmet Coskun, Hatice Koseci, Tolga Ata, Serdar Bozkurt, Berna Cil, Timucin Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy |
title | Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy |
title_full | Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy |
title_fullStr | Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy |
title_full_unstemmed | Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy |
title_short | Effect of Microsatellite Status and Pan-Immune-Inflammation Score on Pathological Response in Patients with Clinical Stage III Stomach Cancer Treated with Perioperative Chemotherapy |
title_sort | effect of microsatellite status and pan-immune-inflammation score on pathological response in patients with clinical stage iii stomach cancer treated with perioperative chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537642/ https://www.ncbi.nlm.nih.gov/pubmed/37763744 http://dx.doi.org/10.3390/medicina59091625 |
work_keys_str_mv | AT gulmezahmet effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy AT coskunhatice effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy AT kosecitolga effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy AT ataserdar effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy AT bozkurtberna effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy AT ciltimucin effectofmicrosatellitestatusandpanimmuneinflammationscoreonpathologicalresponseinpatientswithclinicalstageiiistomachcancertreatedwithperioperativechemotherapy |